These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928 [TBL] [Abstract][Full Text] [Related]
6. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Yadlapati A; Groh C; Passman R Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547 [TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398 [TBL] [Abstract][Full Text] [Related]
8. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. Chang HY; Zhou M; Tang W; Alexander GC; Singh S BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985 [TBL] [Abstract][Full Text] [Related]
10. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
11. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA Europace; 2014 Oct; 16(10):1443-9. PubMed ID: 25115168 [TBL] [Abstract][Full Text] [Related]
12. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Healey JS; Eikelboom J; Douketis J; Wallentin L; Oldgren J; Yang S; Themeles E; Heidbuchel H; Avezum A; Reilly P; Connolly SJ; Yusuf S; Ezekowitz M; Circulation; 2012 Jul; 126(3):343-8. PubMed ID: 22700854 [TBL] [Abstract][Full Text] [Related]
13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161 [TBL] [Abstract][Full Text] [Related]
14. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Huisman MV; Quinlan DJ; Dahl OE; Schulman S Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996 [TBL] [Abstract][Full Text] [Related]
15. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Fontaine GV; Mathews KD; Woller SC; Stevens SM; Lloyd JF; Evans RS Clin Appl Thromb Hemost; 2014 Oct; 20(7):665-72. PubMed ID: 24875781 [TBL] [Abstract][Full Text] [Related]